ID
13435
Descripción
Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients receiving antibiotic treatment. The same is true for Clostridium difficile-associated diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The development and evaluation of preventive strategies is one key public health challenge. In the absence of clinically evaluated alternatives, probiotics have been suggested to be beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive and recently published meta-analyses strongly recommended large state-of-the-art clinical trials on probiotic substances for the prevention of AAD and CDAD. Since the efficacy, side-effects and modes of action of different probiotic bacteria and yeast are strain specific, benefits and risks cannot be generalised. The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD. We carry out a randomised, placebo controlled, double blind multicentre clinical trial to evaluate Sac. boulardii for the indication of prevention of AAD and CDAD in 1520 adult, hospitalised patients.
Palabras clave
Versiones (2)
- 9/2/16 9/2/16 -
- 11/2/16 11/2/16 -
Subido en
11 de febrero de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
SacBo PZ: Case Report Form Hospitalization Completion Of Current Visit DRKS00000084 NCT01143272
SacBo PZ: Case Report Form Hospitalization Completion Of Current Visit NCT01143272
Descripción
Investigational Drug Starting Box
Alias
- UMLS CUI-1
- C0013230
Descripción
Investigational Drug Following Boxes
Descripción
Following boxes are necessary if the antibiotic treatment in phase 1 takes longer than 10 days.
Tipo de datos
integer
Unidades de medida
- days
Alias
- UMLS CUI [1,1]
- C0444921
- UMLS CUI [1,2]
- C0003232
Descripción
Therefore the patient need the following amount of following boxes
Tipo de datos
integer
Descripción
Following boxes that were already given to the patient
Tipo de datos
text
Descripción
Number of the following box
Tipo de datos
integer
Descripción
Following box taken home
Tipo de datos
boolean
Similar models
SacBo PZ: Case Report Form Hospitalization Completion Of Current Visit NCT01143272
C0029921 (UMLS CUI [2])
C0003232 (UMLS CUI [1,2])